Scarica l'app Stockscreener
4.73
6.53%
-0.32
Enanta Pharmaceuticals Inc Borsa (ENTA) Ultime notizie
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st
Enanta Pharmaceuticals at H.C. Wainwright: Strategic Shift to Immunology By Investing.com - Investing.com Canada
(ENTA) Proactive Strategies - news.stocktradersdaily.com
Drug Co. Wants Fed. Circ. To Undo Pfizer COVID Patent Win - Law360
Enanta Reveals Latest Autoimmune Drug Progress: Key Presentation March 27 - StockTitan
How To Trade (ENTA) - Stock Traders Daily
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - Yahoo Finance
Enanta Pharmaceuticals Reports Q1 EPS Loss of $1.05, Beating Est - GuruFocus.com
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13 - Business Wire
Breakthrough RSV Treatment Data: Enanta Reveals Phase 2 Results for Dual Drug Programs - Stock Titan
Insider Buying: Jay Luly Acquires 45,000 Shares of Enanta Pharma - GuruFocus.com
Investor Network: Enanta Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Enanta Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
(ENTA) Trading Advice - Stock Traders Daily
Market Watch Highlights: Enanta Pharmaceuticals Inc (ENTA) Ends on an Upturn Note at 8.30 - The Dwinnex
Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded at StockNews.com - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to “Hold” at StockNews.com - Defense World
HC Wainwright Has Pessimistic Outlook of ENTA Q2 Earnings - MarketBeat
Enanta Pharmaceuticals' SWOT analysis: RSV and immunology drive stock outlook - MSN
Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $17.25 - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Purchases $256,050.00 in Stock - MarketBeat
Enanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stock - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to "Sell" at StockNews.com - MarketBeat
JMP Securities maintains Enanta stock with $21 target - MSN
With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns - Yahoo Finance
President of Enanta Pharmaceuticals Picks Up 5.9% More Stock - Yahoo Finance
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Receives "Market Outperform" Rating from JMP Securities - MarketBeat
Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry - Simply Wall St
Enanta Pharmaceuticals’ (ENTA) “Buy” Rating Reiterated at HC Wainwright - Defense World
HC Wainwright maintains $18 target on Enanta shares, affirms Buy - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Releases Quarterly Earnings Results - MarketBeat
Enanta Pharmaceuticals Advances in Virology and Immunology - TipRanks
Enanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stock By Investing.com - Investing.com South Africa
ENANTA Pharmaceuticals CEO Acquires 45,000 Shares - TradingView
Enanta Pharmaceuticals Inc. (ENTA) reports earnings - Quartz
ENANTA PHARMACEUTICALS INC SEC 10-Q Report - TradingView
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Downgraded by StockNews.com to “Sell” - Defense World
JMP Securities maintains Enanta stock with $21 target By Investing.com - Investing.com Australia
JMP Securities Reaffirms “Market Outperform” Rating for Enanta Pharmaceuticals (NASDAQ:ENTA) - Defense World
2.65%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):